May 24, 2023
GeneDx to Participate in Upcoming Investor Conferences in June
Read More
May 23, 2023
GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations
Read More
May 22, 2023
GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement
Read More
May 9, 2023
GeneDx Reports First Quarter 2023 Financial Results and Business Highlights
Read More
May 4, 2023
GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option
Read More
May 3, 2023
GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders
Read More
April 28, 2023
GeneDx Announces Reverse Stock Split
Read More
April 18, 2023
GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
Read More
April 3, 2023
GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel
Read More
March 20, 2023
GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
Read More
Displaying 1 - 10 of 21